We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients.
- Authors
Lippi, Giuseppe; Henry, Brandon M.; Favaloro, Emmanuel J.
- Abstract
Graph: Figure 1: Weighted mean difference (WMD) and 95% confidence interval (95% CI) of soluble urokinase plasminogen activator receptor (suPAR) levels in patients with or without severe coronavirus disease 2019 (COVID-19) illness. Keywords: coronavirus; COVID-19; soluble urokinase plasminogen activator receptor; suPAR EN coronavirus COVID-19 soluble urokinase plasminogen activator receptor suPAR e413 e415 3 10/18/21 20210915 NES 210915 To the Editor, Soluble urokinase-type plasminogen activator receptor (suPAR) is a soluble receptor derived from enzymatic cleavage of the membrane uPAR receptor at the surface of blood mononuclear and endothelial cells in response to a vast array of inflammatory and immunomodulatory stimuli, including viral infections [[1]].
- Subjects
PLASMINOGEN activators; COVID-19; UROKINASE; MEDICAL personnel; COVID-19 pandemic; PROGNOSIS
- Publication
Clinical Chemistry & Laboratory Medicine, 2021, Vol 59, Issue 11, pe413
- ISSN
1434-6621
- Publication type
Letter
- DOI
10.1515/cclm-2021-0561